Key Takeaway: 4D Molecular Therapeutics has reported positive results from a mid-stage trial of its gene therapy for age-related blindness. The therapy significantly reduced the need for standard injections in patients, suggesting it may offer a more effective treatment option. This development could enhance the quality of life for those suffering from vision loss.
Price reaction · baseline $10.41 (2024-10-01 close) · hit pre-market · 1 other FDMT headline(s) in the window, move may be shared
day 0 close · peak
-1.3%
Market Sentiment Analysis
POSITIVE FACTORS
4DMT's gene therapy shows promise in treating age-related vision loss.
Reduced need for standard injections indicates potential for improved patient outcomes.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
Full Press Release Details
Max Bayer
Senior Reporter
4D Molecular Therapeutics’ one-time gene therapy reduced the need for annual injections in patients with age-related blindness in a mid-stage trial.
The company on Wednesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.